Switzerland's Helsinn Group has presented results from two Phase III studies of cachexia drug anamorelin, with which it is planning 2015 filings in the US and Europe. But while the drug hit one of its co-primary endpoints, its failure to hit the second makes its success questionable.
The 12-week studies, ROMANA 1 and ROMANA 2, evaluated the effect of anamorelin on anorexia-cachexia in patients with non-small cell lung cancer (NSCLC). Hitting its first primary endpoint, anamorelin was...